Bain Capital Life Sciences Investors

Latest statistics and disclosures from Bain Capital Life Sciences Investors's latest quarterly 13F-HR filing:

  • Top 5 stock holdings are NUVL, PHVS, NAMS, SWTX, IRON, and represent 55.36% of Bain Capital Life Sciences Investors's stock portfolio.
  • Added to shares of these 2 stocks: TNGX (+$11M), SVRA (+$9.9M).
  • Reduced shares in these 7 stocks: CRNX (-$31M), Cymabay Therapeutics (-$24M), DVAX (-$22M), THRD, PHVS, CARA, IRON.
  • Sold out of its position in THRD.
  • Bain Capital Life Sciences Investors was a net seller of stock by $-62M.
  • Bain Capital Life Sciences Investors has $894M in assets under management (AUM), dropping by -7.91%.
  • Central Index Key (CIK): 0001703031

Tip: Access up to 7 years of quarterly data

Positions held by Bain Capital Life Sciences Investors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Portfolio Holdings for Bain Capital Life Sciences Investors

Bain Capital Life Sciences Investors holds 31 positions in its portfolio as reported in the September 2023 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Nuvalent Inc-a (NUVL) 18.4 $164M 3.6M 45.97
 View chart
Pharvaris N V (PHVS) 11.2 $100M 4.8M 20.87
 View chart
Newamsterdam Pharma Company Ordinary Shares (NAMS) 10.8 $97M 11M 9.25
 View chart
Springworks Therapeutics (SWTX) 8.0 $71M 3.1M 23.12
 View chart
Disc Medicine (IRON) 7.0 $63M 1.3M 46.98
 View chart
Savara (SVRA) 6.0 $54M +22% 14M 3.78
 View chart
Crinetics Pharmaceuticals In (CRNX) 4.2 $38M -44% 1.3M 29.74
 View chart
Tango Therapeutics (TNGX) 3.6 $33M +50% 2.9M 11.26
 View chart
Natera (NTRA) 3.5 $31M 700k 44.25
 View chart
Cabaletta Bio (CABA) 3.4 $30M 2.0M 15.22
 View chart
Aclaris Therapeutics (ACRS) 2.6 $23M 3.4M 6.85
 View chart
Eqrx 2.5 $22M 10M 2.22
 View chart
X4 Pharmaceuticals (XFOR) 1.9 $17M 16M 1.09
 View chart
Arcutis Biotherapeutics (ARQT) 1.8 $16M 3.0M 5.31
 View chart
Nurix Therapeutics (NRIX) 1.6 $14M 1.8M 7.86
 View chart
Cymabay Therapeutics 1.5 $14M -63% 914k 14.91
 View chart
Dynavax Technologies Corp Com New (DVAX) 1.5 $14M -62% 915k 14.77
 View chart
Annexon (ANNX) 1.5 $14M 5.7M 2.36
 View chart
Marinus Pharmaceuticals Com New (MRNS) 1.3 $12M 1.4M 8.05
 View chart
Mersana Therapeutics (MRSN) 1.2 $11M 8.7M 1.27
 View chart
Rapid Micro Biosystems Class A Com (RPID) 1.0 $9.1M 8.4M 1.08
 View chart
Syros Pharmaceuticals Com New (SYRS) 0.9 $8.4M 2.1M 3.95
 View chart
Solid Biosciences Com New (SLDB) 0.9 $7.9M 3.1M 2.52
 View chart
Atea Pharmaceuticals (AVIR) 0.8 $7.5M 2.5M 3.00
 View chart
Nautilus Biotechnology (NAUT) 0.7 $6.3M 2.0M 3.16
 View chart
Xilio Therapeutics (XLO) 0.7 $5.9M 2.8M 2.11
 View chart
2seventy Bio Common Stock (TSVT) 0.6 $5.5M 1.4M 3.92
 View chart
Adagio Therapeutics (IVVD) 0.4 $3.3M 1.9M 1.70
 View chart
C4 Therapeutics Com Stk (CCCC) 0.3 $3.1M 1.6M 1.86
 View chart
Newamsterdam Pharma Company *w Exp 11/22/202 (NAMSW) 0.0 $190k 100k 1.90
 View chart
Cara Therapeutics (CARA) 0.0 $40k -97% 24k 1.68
 View chart

Past Filings by Bain Capital Life Sciences Investors

SEC 13F filings are viewable for Bain Capital Life Sciences Investors going back to 2017

View all past filings